Presbyopia Market
The Presbyopia market report provides current treatment practices, emerging drugs, Presbyopia market share of the individual therapies, current and forecasted Presbyopia market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Presbyopia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Presbyopia Epidemiology
The Presbyopia epidemiology division provides insights about historical and current Presbyopia patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
In the year 2020, the total prevalent case of Presbyopia was 286,994,105 cases in the 7MM which are expected to grow during the forecast period, i.e., 2021–2030.
The disease epidemiology covered in the report provides historical as well as forecasted Presbyopia epidemiology [segmented as Total Prevalent Cases of Presbyopia, Total Diagnosed Cases of Presbyopia, Total Age-specific Cases of Presbyopia, Gender-specific Cases of Presbyopia, Severity-specific Cases of Presbyopia, and Total Treated cases of Presbyopia] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Country Wise- Presbyopia Epidemiology
Estimates show that the highest cases of Presbyopia in the 7MM were in the United States, followed by Germany, Japan, Italy, France, the United Kingdom, and Spain in 2020.
Presbyopia Drug Chapters
The drug chapter segment of the Presbyopia report encloses the detailed analysis of Presbyopia late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Presbyopia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Presbyopia Emerging Drugs
PresbiDrops/CSF-1 (Orasis Pharmaceuticals)
CSF-1, also known as PresbiDrops, is a corrective eye drop being developed by Orasis Pharmaceuticals to offer an alternative to reading glasses and intrusive surgical procedures to enhance the quality of life for people with presbyopia. CSF-1 is delivered directly to the eyes as a topical solution and provides a patented blend of current and well-studied ingredients with the potential for close vision restoration in people with presbyopia. It is being developed to improve near visual acuity by pupil modulation, resulting in a “pinhole effect” and an increase in the depth of field, thus increasing the ability to focus on near objects. A Phase II clinical trial of CSF-1 showed very high success rates for two-line and three-line improvement, attesting that CSF-1 eliminates the need for reading glasses for many people. Also, CSF-1 had no negative impact on distance vision, night vision, and visual field.
MicroLine/Pilocarpine Ophthalmic (Eyenovia)
MicroLine is Eyenovia’s patented pilocarpine presbyopia formulation. Pilocarpine is a well-characterized drug, with several trials showing its ability to improve the depth of focus of the eye to reverse the age-related loss of accommodative effect and enhance close vision. Pilocarpine works by creating a pinhole effect, which is done by constricting the pupil of the eye, similar to a pinhole camera, and bringing near and medium-distance objects into focus. The MicroLine of Eyenovia is a patented micro-dosed pilocarpine formulation distributed through the Optejet dispenser. Currently, the company has initiated a Phase III clinical trial wherein volunteer participants will be evaluated for eligibility during a screening visit. The US FDA has also accepted Eyenovia’s IND application for MicroLine in December 2020 for the improvement in near vision in patients with presbyopia.
UNR844/Lipoic acid choline ester (Novartis)
UNR844, formerly known as EV06, is being developed by Novartis as a new topical agent to boost the accommodative spectrum for presbyopia. UNR844 contains lipoic acid choline ester, a decreasing agent intended to decrease the disulfide bonds that form between proteins of the lens, thereby raising the crystalline lens deformability and increasing the accommodative amplitude. Novartis gained possession of this drug in December 2016 with the acquisition of Encore Vision. Currently, UNR844 has completed the Phase II of the clinical developmental stage.
AGN-190584 (AbbVie)
AbbVie’s Allergan is developing AGN-190584, an investigational optimized formulation of pilocarpine. It is a cholinergic muscarinic receptor agonist being investigated for treating symptoms associated with presbyopia as a topical, once-daily drop delivered by a proprietary vehicle. The goal of this pupil size reduction is to increase the depth of focus. Secondarily, it is believed to allow for increased accommodation through mild contraction of the ciliary muscle. AGN-190584 for the treatment of symptoms associated with presbyopia met their primary efficacy endpoint in Phase III GEMINI 1 and 2 clinical trials.
AGN-241622 (AbbVie)
AGN-241622 is a second investigational drug from AbbVie’s Allergan. It is an Alpha 2 agonist being investigated for the treatment of presbyopia; the drug is a small molecule that targets the Alpha 2 Adrenergic Receptor. AGN-241622 is currently being investigated in Phase I/II of clinical studies, and the study is estimated to be completed in August 2022.
Nyxol (Occuphire Pharma)
Nyxol is a preservative-free ophthalmic solution containing 0.75% phentolamine (or 1% phentolamine mesylate), a nonselective alpha-adrenergic antagonist that inhibits the contraction of the smooth muscle of the iris. Nyxol’s potential to improve near vision is based on its mechanism of reducing pupil diameter, which results in an increased depth of focus. It alone has been shown to reduce pupil diameter by approximately 20% and has significantly improved near visual acuity by one eye-chart line for over 24 h after an evening eye drop. It is being developed under the 505(b)(2) pathway.
VTI-001/Brimochol (Visus Therapeutics)
VTI-001, also known as Brimochol, combines two active ingredients: carbachol and brimonidine tartrate. It is the lead investigational medicine candidate being developed by Visus Therapeutics for adults who suffer from presbyopia. The company is investigating the drug as a prescription eye drop designed to correct the loss of near vision associated with presbyopia.
Note: Detailed emerging therapies assessment will be provided in the final report.
Presbyopia Market Outlook
Presbyopia is the gradual reduction in flexibility of the lens of the eye with age. A normal part of aging, presbyopia usually becomes noticeable between the ages of 40 and 50 as an inability to focus on near objects. Patients may experience a noteworthy visual disability if a correction is not made and may also develop problems maintaining the usual levels of activity and productivity at work and everyday activities. The goal of treatment is to compensate for the inability of the eyes to focus on nearby objects. Presbyopia cannot be cured, but properly prescribed glasses or contact lenses can make seeing up close much more comfortable.
The pharmacological control of presbyopia is a desirable option for those affected by presbyopia and with an increasing near vision spectacle dependence. Current clinical management of presbyopia in the United States includes off-label treatment using miotic agents, such as pilocarpine and carbachol. Pharmacological treatment of presbyopia is based on using ophthalmic drops, which by the impact on the ciliary muscle, changes the pupil size and elasticity, improving near vision. Many different modifications, including the combination of two parasympathomimetics and an NSAID, two parasympathomimetics and one parasympatholytic, carbachol 2.25% with brimonidine 0.2%, and a combination of pilocarpine 0.247%, phenylephrine 0.78%, polyethylene glycol 0.09%, nepafenac 0.023%, pheniramine 0.034%, and naphazoline 0.003% were studied.
At present, some companies have initiated clinical trials that investigate new treatment options. Key players such as Orasis Pharmaceuticals (PresbiDrops), Novartis (UNR844), Eyenovia (MicroLine), Allergan (acquired by AbbVie) (AGN-190584 and AGN-241622), Ocuphire Pharma (Nyxol), Visus therapeutics (VTI-001/Brimochol), and several others are investigating their candidates for the management of presbyopia in the 7MM.
The Presbyopia market size in the 7MM is expected to change during the study period 2018–2030. The therapeutic market of Presbyopia in the seven major markets is expected to increase during the study period (2018–2030) with a CAGR of 4%. According to the estimates, the highest market size of Presbyopia is found in the United States followed by Germany.
The United States Market Outlook
The total market size of Presbyopia therapies in the United States is expected to increase with a CAGR of 5.6% in the study period (2018–2030).
EU-5 Countries: Market Outlook
The total market size of Presbyopia therapies in EU-5 countries is expected to increase with a CAGR of 2.3% in the study period (2018–2030).
Japan Market Outlook
The total market size of Presbyopia therapies in Japan is expected to increase with a CAGR of 2.2% in the study period (2018–2030).
Request for sample pages @ Presbyopia Market Size
Table of contents
1. Key Insights
2. Report Introduction
3. Presbyopia Market Overview at a Glance
3.1. Market Share (%) Distribution of Presbyopia in 2018
3.2. Market Share (%) Distribution of Presbyopia in 2030
4. Executive Summary of Presbyopia
5. Presbyopia Market: Future Perspective
6. Epidemiology and Market Methodology
7. Disease Background and Overview
7.1. Introduction
7.1.1. Signs and Symptoms of Presbyopia
7.1.2. Difference between Presbyopia and Hyperopia
7.1.3. Risk Factors and Causes of Presbyopia
7.1.4. Pathophysiology of Presbyopia
7.1.5. Complications of Presbyopia
7.2. Diagnosis of Presbyopia
7.3. Patient History
7.4. Ocular Examination
7.4.1. Visual Acuity
7.4.2. Keratometry/Topography
7.4.3. Refraction
7.4.4. Binocular Vision and Accommodation
7.5. Supplemental Testing
7.6. Eye health evaluation
7.7. Recommended eye examination frequency for pediatric patients and adults
7.8. Differential Diagnosis
8. Early Detection and Prevention of Presbyopia
9. Current Treatment Practices: Presbyopia
9.1. Treatment Algorithm of Presbyopia
9.2. Optical Correction with Spectacle Lenses
9.3. Optical Correction with Contact Lenses
9.4. Surgical options
9.4.1. Conductive keratoplasty (CK)
9.4.2. Monovision LASIK for presbyopia
9.4.3. Laser-Assisted Sub Epithelial Keratectomy (LASEK)
9.4.4. Difference between LASIK and LASEK
9.4.5. Photorefractive keratectomy (PRK)
9.4.6. IntraCor – Corneal Surgery
9.4.7. Multifocal Corneal Ablation
9.5. Corneal inlay
9.6. Lens implants
9.7. Current Pharmacological Treatment
10. Guidelines of Presbyopia
10.1. Management Strategies for Correction of Presbyopia- American Optometric Association
10.1.1. General Considerations
10.1.2. Patient Education
10.1.3. Prognosis and Follow-up
10.2. NICE guidance for corneal inlay implantation for correction of presbyopia
10.3. Management guidelines by the American Academy of Ophthalmology
10.4. Analysis of Guidelines
11. Epidemiology and Patient Population
11.1. Key Findings
11.2. Epidemiology of Presbyopia
11.3. Epidemiology Scenario: 7MM
11.3.1. Total Prevalent Cases of Presbyopia
11.3.2. Total Diagnosed Cases of Presbyopia
11.3.3. Total Age-specific Cases of Presbyopia
11.3.4. Gender-specific Cases of Presbyopia
11.3.5. Severity-specific Cases of Presbyopia
11.3.6. Total Treated Cases of Presbyopia
12. The United States
12.1. Total Prevalent Cases of Presbyopia
12.2. Total Diagnosed Cases of Presbyopia
12.3. Total Age-specific Cases of Presbyopia
12.4. Gender-specific Cases of Presbyopia
12.5. Severity-specific Cases of Presbyopia
12.6. Total Treated Cases of Presbyopia
13. EU-5
13.1. Germany
13.1.1. Total Prevalent Cases of Presbyopia
13.1.2. Total Diagnosed Cases of Presbyopia
13.1.3. Total Age-specific Cases of Presbyopia
13.1.4. Gender-specific Cases of Presbyopia
13.1.5. Severity-specific Cases of Presbyopia
13.1.6. Total Treated Cases of Presbyopia
13.2. France
13.2.1. Total Prevalent Cases of Presbyopia
13.2.2. Total Diagnosed Cases of Presbyopia
13.2.3. Total Age-specific Cases of Presbyopia
13.2.4. Gender-specific Cases of Presbyopia
13.2.5. Severity-specific Cases of Presbyopia
13.2.6. Total Treated Cases of Presbyopia
13.3. Italy
13.3.1. Total Prevalent Cases of Presbyopia
13.3.2. Total Diagnosed Cases of Presbyopia
13.3.3. Total Age-specific Cases of Presbyopia
13.3.4. Gender-specific Cases of Presbyopia
13.3.5. Severity-specific Cases of Presbyopia
13.3.6. Total Treated Cases of Presbyopia
13.4. Spain
13.4.1. Total Prevalent Cases of Presbyopia
13.4.2. Total Diagnosed Cases of Presbyopia
13.4.3. Total Age-specific Cases of Presbyopia
13.4.4. Gender-specific Cases of Presbyopia
13.4.5. Severity-specific Cases of Presbyopia
13.4.6. Total Treated Cases of Presbyopia
13.5. The United Kingdom
13.5.1. Total Prevalent Cases of Presbyopia
13.5.2. Total Diagnosed Cases of Presbyopia
13.5.3. Total Age-specific Cases of Presbyopia
13.5.4. Gender-specific Cases of Presbyopia
13.5.5. Severity-specific Cases of Presbyopia
13.5.6. Total Treated Cases of Presbyopia
14. Japan
14.1. Total Prevalent Cases of Presbyopia
14.2. Total Diagnosed Cases of Presbyopia
14.3. Total Age-specific Cases of Presbyopia
14.4. Gender-specific Cases of Presbyopia
14.5. Severity-specific Cases of Presbyopia
14.6. Total Treated Cases of Presbyopia
15. Patient Journey
16. Key Endpoints in Presbyopia Clinical Trials
17. Emerging Therapies
17.1. AGN-190584: Allergan (acquired by AbbVie)
17.1.1. Product Description
17.1.2. Other Developmental Activities
17.1.3. Clinical Development
17.1.4. Safety and Efficacy
17.2. MicroLine (Pilocarpine Ophthalmic): Eyenovia
17.2.1. Product Description
17.2.2. Other Developmental Activities
17.2.3. Clinical Development
17.3. PresbiDrops (CSF-1): Orasis Pharmaceuticals
17.3.1. Product Description
17.3.2. Other Developmental Activities
17.3.3. Clinical Development
17.3.4. Safety and Efficacy
17.4. Nyxol (Phentolamine Mesylate): Ocuphire Pharma
17.4.1. Product Description
17.4.2. Other Developmental Activities
17.4.3. Clinical Development
17.5. UNR844 (Lipoic acid choline ester; formerly known as EV06): Novartis
17.5.1. Product Description
17.5.2. Other Developmental Activities
17.5.3. Clinical Development
17.5.4. Safety and Efficacy
17.6. VTI-001 (Brimochol): Visus Therapeutics
17.6.1. Product Description
17.6.2. Other Developmental Activities
17.6.3. Clinical Development
17.7. AGN-241622: Allergan (acquired by AbbVie)
17.7.1. Product Description
17.7.2. Clinical Developmental
18. Conjoint Analysis of Presbyopia
19. Presbyopia: 7 Major Market Analysis
19.1. Key Findings
19.2. Market Outlook
19.3. 7MM Market Size
19.3.1. Total Market Size of Presbyopia in the 7MM
19.3.2. Market Size of Presbyopia by Therapies in the 7MM
20. The United States Market Size
20.1. Total Market Size of Presbyopia in the United States
20.2. Market Size of Presbyopia by Therapies in the United States
21. EU-5 Market Size
21.1. Germany
21.1.1. Total Market size of Presbyopia in Germany
21.1.2. Market Size of Presbyopia by Therapies in Germany
21.2. France
21.2.1. Total Market size of Presbyopia in France
21.2.2. Market Size of Presbyopia by Therapies in France
21.3. Italy
21.3.1. Total Market size of Presbyopia in Italy
21.3.2. Market Size of Presbyopia by Therapies in Italy
21.4. Spain
21.4.1. Total Market size of Presbyopia in Spain
21.4.2. Market Size of Presbyopia by Therapies in Spain
21.5. The United Kingdom
21.5.1. Total Market size of Presbyopia in the United Kingdom
21.5.2. Market Size of Presbyopia by Therapies in the United Kingdom
22. Japan
22.1. Total Market size of Presbyopia in Japan
22.2. Market Size of Presbyopia by Therapies in Japan
23. Market Access and Reimbursement
24. KOL Views
25. Market Drivers
26. Market Barriers
27. SWOT Analysis
28. Unmet Needs
29. Appendix
29.1. Bibliography
29.2. Report Methodology
30. DelveInsight Capabilities
31. Disclaimer
32. About DelveInsight
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/